The global viral clearance market size accounted for USD 0.93 billion in 2024, grew to USD 1.13 billion in 2025 and is expected to be worth around USD 6.78 billion by 2034, registering a healthy CAGR of 22.01% between 2024 and 2034. The North America viral clearance market size is calculated at USD 430 million in 2024 and is estimated to grow at a fastest CAGR of 22.10% during the forecast period.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Viral Clearance Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Viral Clearance Market Revenue and Volume, by Method, 2024-2034
8.1.1 Viral Removal
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Viral Inactivation
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1. Viral Clearance Market Revenue and Volume, by Application, 2024-2034
9.1.1. Recombinant Proteins
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Blood and Blood Products
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Cellular and Gene Therapy Products
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
9.1.4. Vaccine
9.1.4.1. Market Revenue and Volume Forecast (2021-2034)
9.1.5. Others
9.1.5.1. Market Revenue and Volume Forecast (2021-2034)
10.1. Viral Clearance Market Revenue and Volume, by End-user, 2024-2034
10.1.1. Pharmaceutical and Biotechnology Companies
10.1.1.1. Market Revenue and Volume Forecast (2021-2034)
10.1.2. Contract Research Organizations
10.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1.3. Academic Research Institutes
10.1.3.1. Market Revenue and Volume Forecast (2021-2034)
10.1.4. Others
10.1.4.1. Market Revenue and Volume Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.1.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.1.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.1.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.1.4.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.1.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.1.5.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.2.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.2.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.2.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.2.4.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.2.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.2.5.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.2.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.2.6.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.2.7.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.2.7.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.3.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.3.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.3.4.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.3.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.3.5.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.3.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.3.6.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.3.7.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.3.7.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.4.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.4.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.4.4.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.4.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.4.5.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.4.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.4.6.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.4.7.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.4.7.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.5.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.5.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.5.4.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Method (2021-2034)
11.5.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.5.5.3. Market Revenue and Volume Forecast, by End-user (2021-2034)
12.1. Merck KGaA
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Vironova
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Kedrion
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Sartorius AG
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Syngene International Limited
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Microbiologics
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Clean Cells
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. ViruSure GmbH
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Charles River Laboratories
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. WuXi Biologics
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample